Welcome to RMD Open
playlist_add
BMJ and EULAR are launching a new rheumatic and musculoskeletal diseases journal, RMD Open, and Editor-in-Chief Bernard Combe explains what readers and authors can look forward to.
More episodes from RMD Open: Rheumatic and Musculoskeletal Diseases
Feb 21, 2023
Promoting gender equity in academic rheumatology
In this podcast, Dr. Javier Rodríguez-Carrio talks to Dr. Pavel Ovseiko and Prof. Laura Coates about the recent paper on gender equity in academic rheumatology which emerged from a EULAR task force. They discuss the current situation of gender equity in academic rheumatology across Europe, the pros and cons of potential interventions to accelerate gender-equitable career advancement in this field and how and these be applied in the short- and long-term. Link to the viewpoint: https://rmdopen.bmj.com/content/8/2/e002518.long
Listen to more episodes of RMD Open: https://podcasts.apple.com/gb/podcast/rmd-open-rheumatic-and-musculoskeletal-diseases/id1237127864
playlist_add
Jan 13, 2023
Autoantibodies against PTM proteins as biomarkers for lupus
Autoantibodies against post-translationally modified proteins (PTM) are described in various rheumatic diseases and facilitate diagnosis and patient stratification. Researchers from the Leiden University Medical Center analysed the presence of autoantibodies against six different post-translational modifications in a cohort of patients with neuropsychiatric lupus. In this podcast, Leendert Trouw, Rory Monahan and Michelle van den Beukel discuss the results of their study with the ARD/RMDopen social media advisor Caroline Ospelt. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002079
Listen to more episodes of RMD Open: https://podcasts.apple.com/gb/podcast/rmd-open-rheumatic-and-musculoskeletal-diseases/id1237127864
playlist_add
Jul 15, 2022
Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study
In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236
(1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)
playlist_add